An Expedition of FDA-Approved Anticancer Drugs in 2024: Synthetic Routes, Mechanisms of Action, and Clinical Indications - PubMed
4 hours ago
- #FDA-approved drugs
- #targeted therapy
- #cancer therapy
- In 2024, the FDA approved 56 anticancer drugs, including 36 small molecules and 20 macromolecular monoclonal antibody conjugates.
- Small molecule drugs include kinase inhibitors (e.g., Ribociclib, Imatinib Mesylate), antimetabolites (e.g., Fluorouracil), DNA-damaging agents (e.g., Mitomycin), immune modulators (e.g., Pomalidomide), and hormonal antagonists (e.g., Abiraterone Acetate).
- Macromolecular therapeutics feature monoclonal antibodies (e.g., Keytruda, Tecentriq) and antibody-drug conjugates (e.g., Enhertu, Elahere) for targeted therapy and immune checkpoint inhibition.
- The review covers synthetic routes, mechanisms of action, and clinical applications of these drugs to improve cancer treatment outcomes.
- Analysis of drug structures and targets provides insights into trends and future directions in anticancer drug development.